HMGCR and cancer: Greenaway et al., (2016) proved that the inhibition of the mevalonate pathway using HMG-CoA reductase inhibitors could decrease levels of mevalonate and its downstream products, and thus, may have significant inhibitory influences on cancer cell growth.